BWX Technologies (BWXT) M&A Announcement summary

Deal rationale and strategic fit

• Expands commercial operations and capabilities in commercial nuclear power, nuclear medicine, and clean energy, especially in Canada, the U.S., and Europe.

• Creates a comprehensive portfolio of end-to-end lifecycle services for small modular and large-scale nuclear reactor markets, leveraging Kinectrics' expertise and facilities.

• Magnifies market opportunity with a broader product portfolio, including enhanced isotope production for radiopharmaceuticals.

• Increases global workforce to nearly 10,000 and expands facility capacity.

• Responds to rising global demand for nuclear projects, electrification, decarbonization, and novel nuclear applications.

Financial terms and conditions

• Acquisition price is approximately $525 million, including debt, pension liabilities, and transaction expenses.

• Represents a 14x EBITDA multiple based on 2024 projections; expected to de-rate by one turn in 2025.

• Kinectrics expected to generate nearly $300 million in revenue and just under $40 million EBITDA in 2024.

• Funded through available revolver capacity and assumption of Kinectrics' debt and net pension liabilities; pro forma net leverage expected at 2.75x.

• Modestly accretive to EPS in year one post-close, with incremental free cash flow targeted.

Synergies and expected cost savings

• No significant cost synergies targeted; focus is on investing in and expanding Kinectrics' business and capabilities.

• Combined company covers the full spectrum of commercial nuclear products and services for new and existing infrastructure.

• Anticipates adjusted EBITDA margins consistent with commercial operations and medium-term growth.